Risk assessment and management of post-transplant diabetes mellitus

被引:17
作者
Han, Eugene [1 ,2 ]
Kim, Myoung Soo [3 ]
Kim, Yu Seun [3 ]
Kang, Eun Seok [1 ,2 ,4 ]
机构
[1] Yonsei Univ, Coll Med, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea
[2] Severance Hosp Diabet Ctr, Seoul, South Korea
[3] Yonsei Univ Hlth Syst, Severance Hosp, Dept Transplantat Surg, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Inst Endocrine Res, Seoul, South Korea
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2016年 / 65卷 / 10期
关键词
Diabetes mellitus; Organ transplantation; Risk factors; Management; RENAL-TRANSPLANT PATIENTS; NEW-ONSET HYPERGLYCEMIA; LIPID-LOWERING DRUGS; HEPATITIS-C; KIDNEY-TRANSPLANTATION; CARDIOVASCULAR RISK; CYCLOSPORINE-A; INSULIN-RESISTANCE; METABOLIC SYNDROME; STATIN THERAPY;
D O I
10.1016/j.metabol.2016.07.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The success rate of organ transplantation has been increasing with advances in surgical and pharmacological techniques. However, the number of solid organ transplant recipients who require metabolic disease management is also growing. Post-transplant diabetes mellitus (PTDM) is a common complication after solid organ transplantation and is associated with risks of graft loss, cardiovascular morbidity, and mortality. Other risk factors for PTDM include older age, genetic background, obesity, hepatitis C virus infection, hypomagnesemia, and use of immunosuppressant agents (corticosteroids, calcineurin inhibitors, and mammalian target of rapamycin inhibitor). Management of PTDM should be started before the transplantation plan to properly screen high risk patients. Even though PTDM management is similar to that of general type 2 diabetes, therapeutic approaches. must be made with consideration of drug interactions between immunosuppressive agents, glucose-lowering medications, and graft rejection and function. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:1559 / 1569
页数:11
相关论文
共 129 条
[1]   13. Diabetes Care in the Hospital [J].
不详 .
DIABETES CARE, 2016, 39 :S99-S104
[2]   7. Approaches to Glycemic Treatment [J].
不详 .
DIABETES CARE, 2016, 39 :S52-S59
[3]   4. Prevention or Delay of Type 2 Diabetes [J].
不详 .
DIABETES CARE, 2016, 39 :S36-S38
[4]  
[Anonymous], J HUM GENET
[5]  
[Anonymous], J KOREAN DIABETES
[6]  
Åsberg A, 2003, DRUGS, V63, P367
[7]   Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study [J].
Bae, Jaehyun ;
Lee, Min Jung ;
Choe, Eun Yeong ;
Jung, Chang Hee ;
Wang, Hye Jin ;
Kim, Myoung Soo ;
Kim, Yu Seun ;
Park, Joong-Yeol ;
Kang, Eun Seok .
ENDOCRINOLOGY AND METABOLISM, 2016, 31 (01) :161-167
[8]   Posttransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality [J].
Baid, S ;
Cosimi, AB ;
Farrell, ML ;
Schoenfeld, DA ;
Feng, S ;
Chung, RT ;
Tolkoff-Rubin, N ;
Pascual, M .
TRANSPLANTATION, 2001, 72 (06) :1066-1072
[9]   IL-6 promoter polymorphism-174 is associated with new-onset diabetes after transplantation [J].
Bamoulid, Jamal ;
Courivaud, Cecile ;
Deschamps, Marina ;
Mercier, Patricia ;
Ferrand, Christophe ;
Penfornis, Alfred ;
Tiberghien, Pierre ;
Chalopin, Jean-Marc ;
Saas, Philippe ;
Ducloux, Didier .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (08) :2333-2340
[10]   Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus [J].
Bloom, RD ;
Rao, V ;
Weng, F ;
Grossman, RA ;
Cohen, D ;
Mange, KC .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (05) :1374-1380